Posology: Adults, including the elderly: The recommended dose is 5 mg Solifenacin succinate once daily. If needed, the dose may be increased to 10 mg Solifenacin succinate once daily.
Pediatric population: The safety and efficacy of Solifenacin succinate in children have not yet been established. Therefore, Solifenacin succinate should not be used in children.
Patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance > 30 mL/min). Patients with severe renal impairment (creatinine clearance ≤ 30 mL/min) should be treated with caution and receive no more than 5 mg once daily.
Patients with hepatic impairment: No dose adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) should be treated with caution and receive no more than 5 mg once daily.
Potent inhibitors of cytochrome P450 3A4: The maximum dose of Solifenacin succinate should be limited to 5 mg when treated simultaneously with Ketoconazole or therapeutic doses of other potent CYP3A4-inhibitors e.g. Ritonavir, Nelfinavir, Itraconazole.
Method of administration: Solifenacin succinate should be taken orally and should be swallowed whole with liquids. It can be taken with or without food.